Our Clinical Pipeline
7 compounds across 5 development stages, targeting diseases with significant unmet medical need.
Pipeline Overview
Nexavitol
Non-Small Cell Lung Cancer
A selective KRAS G12C inhibitor demonstrating significant tumor regression in late-stage trials.
Cardivex
Heart Failure with Reduced Ejection Fraction
First-in-class cardiac myosin activator approved in 47 countries for HFrEF management.
Neuralyx
Early-Onset Alzheimer's Disease
Anti-amyloid monoclonal antibody targeting tau aggregation in early cognitive decline.
Immucore-7
Rheumatoid Arthritis
Bispecific antibody targeting IL-6 and TNF-α pathways for refractory RA patients.
Hepatovir
Chronic Hepatitis B
Novel capsid assembly modulator with functional cure potential in CHB patients.
Renalstat
Diabetic Kidney Disease
SGLT2/SGLT1 dual inhibitor with renoprotective properties beyond glycemic control.
Oncovax-3
Triple-Negative Breast Cancer
mRNA-based personalized neoantigen vaccine platform in preclinical development.
The Science Behind Our Pipeline
Four proprietary technology platforms that give us a sustainable competitive advantage in discovering and developing next-generation medicines.
Small Molecule Design
Our computational chemistry platform uses AI-driven structure-based drug design to identify and optimize small molecules with superior selectivity and pharmacokinetic profiles.
Biologics & Antibodies
Our CrossLink™ bispecific antibody platform enables simultaneous engagement of two disease targets, unlocking therapeutic potential beyond conventional monoclonal antibodies.
mRNA Therapeutics
Leveraging proprietary lipid nanoparticle delivery technology, we are developing personalized mRNA-based cancer vaccines and protein replacement therapies.
Targeted Protein Degradation
Our PROTAC and molecular glue programs harness the cell's own ubiquitin-proteasome system to eliminate disease-causing proteins previously considered undruggable.